Drug Trial Radar · NCT01373983
Intrathecal Bolus Doses of Ziconotide
Last checked: Nov 20, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Aug 2011
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- University Hospital, LinkoepingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 15, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if the effect of ziconotide can be tested by intrathecal bolus doses.
Conditions
- Peripheral Neuropathy
Interventions
ZiconotideDrug
1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual Analogue Scale Pain Intensity, VASPI, 0-100 mmTime frame: VASPI before injection and then each hour after injection, for 6 hours.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pain and Rehabilitation Centre, University Hospital
Linköping, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.